These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 22585696)
1. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Garcia-Manero G; Tambaro FP; Bekele NB; Yang H; Ravandi F; Jabbour E; Borthakur G; Kadia TM; Konopleva MY; Faderl S; Cortes JE; Brandt M; Hu Y; McCue D; Newsome WM; Pierce SR; de Lima M; Kantarjian HM J Clin Oncol; 2012 Jun; 30(18):2204-10. PubMed ID: 22585696 [TBL] [Abstract][Full Text] [Related]
2. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412 [TBL] [Abstract][Full Text] [Related]
4. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519 [TBL] [Abstract][Full Text] [Related]
5. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576 [TBL] [Abstract][Full Text] [Related]
6. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434 [TBL] [Abstract][Full Text] [Related]
8. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352 [TBL] [Abstract][Full Text] [Related]
9. Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. Shadman M; Mawad R; Dean C; Chen TL; Shannon-Dorcy K; Sandhu V; Hendrie PC; Scott BL; Walter RB; Becker PS; Pagel JM; Estey EH Am J Hematol; 2015 Jun; 90(6):483-6. PubMed ID: 25689471 [TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425 [TBL] [Abstract][Full Text] [Related]
12. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616 [TBL] [Abstract][Full Text] [Related]
13. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629 [TBL] [Abstract][Full Text] [Related]
14. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470 [TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266 [TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Ruutu T; Hänninen A; Järventie G; Koistinen P; Koivunen E; Kätkä K; Nousiainen T; Oksanen K; Pelliniemi TT; Remes K; Timonen T; Volin L; Elonen E Leuk Res; 1997 Feb; 21(2):133-8. PubMed ID: 9112430 [TBL] [Abstract][Full Text] [Related]
18. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836 [TBL] [Abstract][Full Text] [Related]
19. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Estey EH; Kantarjian H; Keating M Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]